N. Lunde

发表

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

F. C. Dougherty, M. Salifu, S. Fishbane, 2007, Clinical therapeutics.

Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment

J. Wagner, K. Lasseter, T. Marbury, 2011, Journal of clinical pharmacology.

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

J. Wagner, K. Lasseter, R. Robson, 2009, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

T. Rushmore, H. Greenberg, E. Carlini, 2009, Clinical pharmacology and therapy.

Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency

J. Wagner, J. Stone, M. Stroh, 2009, American journal of therapeutics.

Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension

T. Marbury, A. Carr, R. Pordy, 1997 .

A Comparison of Dosing Regimens of Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in CKD Stages 3 and 4

H. Abboud, D. Batlle, J. Melnick, 2006, American Journal of Nephrology.

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

S. Swan, T. Marbury, M. Toh, 2010, Journal of clinical pharmacology.

Unusual causes of peritonitis in patients undergoing continuous peritoneal dialysis with emphasis on Listeria monocytogenes.

R. Swartz, J. Messana, N. Lunde, 1992, Journal of the American Society of Nephrology : JASN.

Increased Monocyte Chemiluminescence in Cystic Fibrosis Patients and in their Parents

P. Quie, W. Regelmann, N. Lunde, 1986, Pediatric Research.

Successful use of cuffed central venous hemodialysis catheters inserted percutaneously.

W. Weitzel, R. Swartz, J. Messana, 1994, Journal of the American Society of Nephrology : JASN.

Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.

T. Marbury, A. Carr, R. Pordy, 1997, Clinical Therapeutics.

Comparison of mortality risk by choice of CAPD versus hemodialysis among elderly patients.

R. Wolfe, K. Guire, F. Port, 1991, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.